Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals (Nasdaq:XENE) announced a significant regulatory milestone in its collaboration with Neurocrine Biosciences (Nasdaq:NBIX), resulting in a $15 million aggregate payment to Xenon. The FDA has accepted a protocol amendment that permits inclusion of pediatric patients aged 2-11 in the Phase 2 study of NBI-921352 for SCN8A developmental and epileptic encephalopathy. The payment consists of $6.75 million in cash and an $8.25 million equity investment at a premium price of $31.855 per share. This collaboration aims to enhance epilepsy treatment options for young patients.
Xenon Pharmaceuticals (Nasdaq:XENE) announced its key milestones for 2022, focusing on its lead product, XEN1101, which showed strong efficacy in a Phase 2b clinical trial for focal epilepsy. Plans include an FDA meeting in Q2 2022 and initiating a Phase 3 program later in the year. The company also aims to explore XEN1101 for major depressive disorder. Ongoing pediatric trials for XEN496 are expected to complete in early 2023. Collaborations with Neurocrine Biosciences and Pacira BioSciences are also highlighted, with potential milestone payments pending.
Xenon Pharmaceuticals (Nasdaq:XENE) announced promising results from the Phase 2b X-TOLE trial of XEN1101 for focal epilepsy, with statistically significant seizure reduction (p0.001) across all dose groups. The 25 mg and 20 mg doses achieved median reductions of 52.8% and 46.4% in monthly seizures, respectively. The trial also demonstrated efficacy for difficult-to-treat patients. Xenon plans a Phase 3 trial and has long-term studies underway, reflecting strong potential for XEN1101 in market.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced its participation in the Annual Meeting of the American Epilepsy Society (AES 2021), highlighting significant updates on its neurology programs. CEO Ian Mortimer emphasized the advancement of XEN1101 and XEN496, with presentations scheduled to showcase Phase 2b clinical trial results and pre-clinical data on epilepsy treatments. A conference call is set for December 3, 2021, to discuss these results. The company aims to address unmet medical needs in epilepsy through innovative therapies.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that CEO Ian Mortimer and CFO Sherry Aulin will speak at three upcoming virtual investor conferences. The Guggenheim 3rd Annual Neuro/Immunology Conference will take place on November 15, 2021, featuring one-on-one meetings. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 17, 2021, including a fireside chat at 1:20 pm ET. Lastly, the Jefferies London Healthcare Conference is set for November 18, 2021, with an on-demand fireside chat starting at 8:00 am GMT. For updates, visit investor.xenon-pharma.com.
Xenon Pharmaceuticals (Nasdaq:XENE) reported promising insights from its Phase 2b X-TOLE clinical trial for XEN1101, showing significant reductions in focal seizure frequency among adult patients. The therapy is designed for easy administration with once-daily dosing. With $249.6 million in cash and equivalents as of September 30, 2021, and anticipated cash flow until at least 2024, the company is set for the initiation of its Phase 3 trial in adult focal epilepsy in late 2022. Total revenue for Q3 2021 reached $8.1 million, up from $6.6 million a year earlier.
Xenon Pharmaceuticals (Nasdaq:XENE) will report its third quarter 2021 financial results on November 10, 2021, after U.S. market close. A live conference call and webcast will take place at 4:30 pm ET to discuss these results and provide a corporate update. Investors can access the webcast through the company's website. As a clinical-stage biopharmaceutical company, Xenon focuses on developing therapies for neurological disorders, particularly epilepsy, addressing significant unmet medical needs.
Xenon Pharmaceuticals Inc. has successfully closed its underwritten public offering of 10,000,000 common shares, including 1,525,423 shares from the underwriters’ option, and pre-funded warrants for 1,694,915 shares. The shares were priced at $29.50 each, with pre-funded warrants at $29.4999. The gross proceeds from this offering totaled approximately $345 million, prior to expenses. The offering followed an effective shelf registration statement filed with the SEC on October 4, 2021.
Xenon Pharmaceuticals has announced a public offering of 8,474,577 common shares and 1,694,915 pre-funded warrants, priced at $29.50 and $29.4999 respectively. The offering aims to raise approximately $300 million in gross proceeds, which will support the company's clinical stage developments. The offering is set to close on or about October 8, 2021. The underwriters have a 30-day option to purchase an additional 1,525,423 shares at the offering price. Jefferies, SVB Leerink, Stifel, and RBC Capital Markets are leading the offering.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has initiated an underwritten public offering of $250 million in common shares, with an option for underwriters to purchase an additional $37.5 million. The offering is made under an existing shelf registration statement filed with the SEC. Notably, this process is subject to market conditions, and completion is not guaranteed. Notable underwriters include Jefferies, SVB Leerink, Stifel, and RBC Capital Markets. The company emphasizes that no securities are being offered in Canada.